Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, PR China.
Med Hypotheses. 2011 Feb;76(2):234-6. doi: 10.1016/j.mehy.2010.10.005. Epub 2010 Nov 10.
Blood glucose control has been a main focus for the treatment of type 2 diabetes. However, poor control and side-effect still are urgent problems to be solved. According to common blood glucose variability and its extremely deleterious diabetic-related complications in clinical practice, it should be considered as a potential key target. And β-cell failure has been approved that it can be reversible for early type 2 diabetes, which suggests another promising target. In this hypothesis, we propose a novel treatment strategy against on the two targets. An intelligent double-target drug delivery system is presented and characterized by dual-responsive functional gates for glucose sensitivity used controlled-release hypoglycemic agents and a sustained-release osmotic pump loaded drugs to repair impaired β-cell into the repository, respectively. The proposition may provide a new early therapeutic strategy for type 2 diabetes in order to better hold blood glucose homeostasis.
血糖控制一直是治疗 2 型糖尿病的主要关注点。然而，控制不佳和副作用仍然是亟待解决的问题。根据临床实践中常见的血糖变异性及其极其有害的糖尿病相关并发症，它应该被视为一个潜在的关键靶点。β细胞衰竭已被证实可逆转早期 2 型糖尿病，这提示了另一个有前途的靶点。在这个假设中，我们针对这两个靶点提出了一种新的治疗策略。我们提出了一种智能双靶点药物传递系统，该系统具有双重响应功能门，用于葡萄糖敏感性，分别使用控释降糖药物和装载药物的持续释放渗透压泵来修复受损的β细胞进入储存库。这一建议可能为 2 型糖尿病提供一种新的早期治疗策略，以便更好地维持血糖稳态。
